All Stories

  1. Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

    Article • Medicine Advances, December 2023, Tsinghua University Press

    Professor Yi-Long Wu

  2. Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules

    Article • Journal of Extracellular Vesicles, September 2019, Taylor & Francis

    Professor Yi-Long Wu

  3. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer

    Article • Current Medical Research and Opinion, July 2019, Taylor & Francis

    Professor Yi-Long Wu

  4. Familial association of lung cancer with liver cancer in first-degree relatives

    Article • Cancer Management and Research, June 2019, Dove Medical Press

    Professor Yi-Long Wu

  5. DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

    Article • OncoImmunology, November 2018, Taylor & Francis

    Professor Yi-Long Wu, Professor Yangqiu Li

  6. Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

    Article • OncoTargets and Therapy, November 2018, Dove Medical Press

    Professor Yi-Long Wu, Shun Lu, angela Märten

  7. Prophylactic air-extraction strategy after thoracoscopic wedge resection

    Article • Thoracic Cancer, September 2018, Wiley

    Professor Yi-Long Wu

  8. Heterogeneous responses and resistant mechanisms to crizotinib in ALK -positive advanced non-small cell lung cancer

    Article • Thoracic Cancer, July 2018, Wiley

    Professor Yi-Long Wu

  9. Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non‐Small Cell Lung Cancer

    Article • The Oncologist, January 2017, Alphamed Press

    Professor Yi-Long Wu

  10. Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation

    Article • Thoracic Cancer, November 2016, Wiley

    Professor Yi-Long Wu

  11. Surgery in oligometastatic NSCLC patients in the targeted therapy era

    Article • Lung Cancer Management, November 2016, Future Medicine

    Professor Yi-Long Wu

  12. Comparison of three‐dimensional and two‐dimensional visualization in video‐assisted thoracoscopic lobectomy

    Article • Thoracic Cancer, May 2016, Wiley

    Professor Yi-Long Wu

  13. Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib

    Article • OncoTargets and Therapy, May 2015, Dove Medical Press

    Professor Yi-Long Wu

  14. Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

    Article • Lung Cancer Targets and Therapy, February 2014, Taylor & Francis

    Professor Yi-Long Wu